Overall survival at 5 years of follow-up from a phase 3 trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma / Ascierto, P. - In: JOURNAL OF TRANSLATIONAL MEDICINE. - ISSN 1479-5876. - 17:(2019). [10.1186/s12967-018-1745-7]
Overall survival at 5 years of follow-up from a phase 3 trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Ascierto P
2019
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
